245 First Street - 18th Floor
Fax: 617- 444-8405
About GENFIT CORP.Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.
Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.
Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.
Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001
159 articles with GENFIT CORP.
6/27/2019Biotech and pharma companies from across the globe share pipeline and business updates.
GENFIT and Terns Pharmaceuticals Announce $228MM Strategic Partnership to Develop and Commercialize Elafibranor in Greater China
GENFIT announced the signing of a licensing and collaboration agreement with Terns Pharmaceuticals, a global biopharmaceutical company based in the U.S. and China with a focus on developing novel and combination therapies to treat liver disease.
GENFIT announced the results of the voting by shareholders at the Ordinary Shareholders’ Meeting which took place on June 13, 2019, in Lille, France.
A year ago, GENFIT gathered an international coalition to support The NASH Education Program and launch the 1st successful edition of International NASH Day
GENFIT announced the launch of a P2 clinical trial evaluating elafibranor’s activity on liver fat quantity and – most importantly – fat composition in nonalcoholic fatty liver disease (NAFLD) patients.
GENFIT: Positive 36-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH
Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data
GENFIT today announced that it published in May 8, 2019’s French legal announcements bulletin (Bulletin des Annonces Légales Obligatoires) its convening notice to the Ordinary Shareholders’ Meeting to be held on Thursday, June 13, 2019, at 2:30pm, at the Faculty of Pharmaceutical & Biological Sciences of Lille, located Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.
Following the capital increase and listing on Nasdaq, cash and cash equivalents totaled €314.1 million as of March 31, 2019
GenFit’s lead product candidate elafibranor snagged Breakthrough Therapy Designation from the U.S. Food and Drug Administration as a treatment for Primary Biliary Cholangitis (PBC) following strong Phase II results that demonstrated the safety and efficacy of the medication.
GENFIT announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC
FDA grants elafibranor Breakthrough Therapy Designation, based on Phase 2 data, for treatment of PBC (Primary Biliary Cholangitis) in adults with inadequate response to UDCA
GENFIT to Present Additional Data from the Positive Phase 2 Clinical Trial Evaluating Elafibranor in Primary Biliary Cholangitis at the International Liver Congress™ 2019
New data also suggest an improvement in pruritus – a major symptom of PBC – with a median change in VAS of -24% (80mg) and -49% (120mg) vs. -7% (placebo)
GENFIT announces Upcoming Presentations on NASH, PBC and Diagnostics at the European Association for the Study of the Liver (EASL) International Liver Congress 2019
Elafibranor Phase 2 data in PBC accepted for late-breaker oral presentation
Genfit, with offices in Lille, France and Cambridge, Mass., launched its initial public offering (IPO) on the Nasdaq on March 27. Dean Hum, chief operating officer of Genfit, took time out to speak with BioSpace about the company, the IPO and elafibranor.
A summary of IPOs from companies in the biotech and pharma world since March 1, 2019.
GENFIT is a French biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases
March has been a busy month for biopharma and medical device company initial public offerings. Here’s a look at the top IPO stories for the month.
France-based GenFit launched its $132 million initial public offering plans in order to raise funds that will be used to support the Phase III trial and planned commercialization of its elafibranor compound for non-alcoholic steatohepatitis (NASH).
GENFIT S.A. announced its intention to issue and sell, subject to market and other conditions, 5,000,000 of its ordinary shares in a global offering to specified categories of investors, comprised of an initial public offering of American Depositary Shares, each representing one ordinary share, in the United States, and a concurrent private placement of ordinary shares in Europe and other countries outside of the US.
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
FDA accepts study protocol, providing green light for GENFIT to initiate Phase 2 clinical trial in pediatric NASH